Age-related macular degeneration is ubiquitous. Nearly all older Americans have at least a few drusen, and many actually have the atrophic form of the disease. Fortunately, choroidal neovascularization (CNV) secondary to age-related macular degeneration is less prevalent, but its visual consequences can be devastating. The Macular Photocoagulation Study (MPS) Group has previously provided treatment recommendations for eyes with CNV in which the posterior edge of the lesion is at least 1 μm from the foveal center.1-4 Practically speaking, laser treatment was considered whenever investigators judged that the CNV did not occupy the center of the foveal avascular zone. In day-to-day practice, however, many patients present with a lesion in which the CNV occupies the foveal avascular zone before any treatment has been applied. In this issue, three MPS articles address the treatment of patients who present with CNV, either new or recurrent, in which the neovascular lesion occupies the